BUZZ-ImmunityBio slumps on stock offering plan** Shares of cancer therapy maker ImmunityBio IBRX.O slide 18.3% to $3.79 premarket
** IBRX late Tuesday announced plan to sell shares in a public offering, but did not disclose the size
** Company plans to use the proceeds to fund the commercialization of its bladder cancer therapy, among other purposes
** IBRX has 696.8 mln outstanding shares and a market capitalization of $3.23 bln - LSEG data
** Jefferies and Piper Sandler are the joint book-running managers for the offering
** As of last close, IBRX shares down 7.6% YTD
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments